AI-driven target discovery uses extensive genomic, transcriptomic, proteomic, and single-cell multi-omics datasets to identify highly expressed tumour-specific antigens and neoantigens with little off-target expression and functional importance for tumour survival or progression including those overexpressed across breast cancer subtypes such as HER2-lo, TNBC, or Luminal B tumours. This evidence concerns the gene ERBB2 and neoplasm.